Posted by Michael Wonder on 20 May 2020
Coverage for biosimilars vs reference products among US commercial health plans
19 May 2020 - The greater use of biosimilars may have the potential to help reduce drug costs.
However, biosimilars have yet to gain traction in the US. In 2010, Congress created an abbreviated licensure pathway for biosimilars, but it is unclear whether and how health plans prioritise coverage of these products.
Three researchers from Tufts University examined how commercial health plans cover biosimilars relative to reference products.
